Avient Corporation Declares Quarterly Cash Dividend
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 16 2026
0mins
Should l Buy AVNT?
Source: PRnewswire
- Quarterly Cash Dividend: Avient Corporation has declared a cash dividend of $0.275 per share, payable on April 3, 2026, to shareholders of record on March 17, 2026, demonstrating the company's commitment to returning value to its shareholders.
- Shareholder Return Strategy: This dividend reflects Avient's strong performance in profitability and cash flow management, aimed at enhancing investor confidence and attracting more long-term investors to the company.
- Global Business Presence: With 9,000 employees worldwide, Avient leverages its extensive technology portfolio and market reach to provide innovative material solutions, driving sustainability and customer success in a rapidly changing world.
- Product Portfolio Expansion: The company continues to expand its offerings, including colorants, advanced composites, and functional additives, to meet the demands of a fast-evolving market, thereby enhancing its competitive position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVNT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVNT
Wall Street analysts forecast AVNT stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 37.630
Low
34.00
Averages
39.80
High
50.00
Current: 37.630
Low
34.00
Averages
39.80
High
50.00
About AVNT
Avient Corporation provides materials solutions. Its portfolio of offerings includes colorants, advanced composites, functional additives, engineered materials, and Dyneema (its ultra-high-molecular-weight polyethylene). Its end markets include consumer, packaging, defense, healthcare, industrial, transportation, building and construction, telecommunications and energy. Its segments include Color, Additives and Inks, and Specialty Engineered Materials. Color, Additives and Inks segment provides specialized custom color and additive concentrates in solid and liquid form for thermoplastics, dispersions for thermosets, as well as specialty inks. Color and additive solutions include an array of colors, special effects and performance-enhancing and sustainable solutions. Specialty Engineered Materials segment provides specialty polymer materials, services and solutions for designers, assemblers and processors of thermoplastic materials across a variety of markets and end-use applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Advanced Materials Science Drives Industry Transformation
- Biomaterials Breakthrough: Recombinant spider silk produced by genetically engineered silkworms exhibits strength surpassing steel and elasticity exceeding Kevlar, already applied in medicine, military, and high-performance textiles, driving sustainability and functionality enhancements.
- Defense Application Innovation: L3Harris Technologies has delivered over 1,000 carbon-fiber bomb casings, reducing collateral damage in urban operations and enhancing operational efficiency, showcasing the immense potential of new materials in the military sector.
- High-Performance Textiles Progress: Kraig Biocraft Laboratories set a record of producing 1.3 metric tons of spider silk in April 2026, with a goal of reaching 10 metric tons monthly, meeting the luxury apparel market's demand for sustainable materials and transforming the textile industry.
- Aerospace Materials Innovation: Aspen Aerogels' next-generation aerogels are providing thermal protection for hypersonic vehicles and reusable spacecraft, marking the convergence of aerospace technology and advanced materials, driving technological advancements in the aerospace sector.
See More
Advanced Materials Technology Drives Industry Transformation
- Biomaterials Breakthrough: Recombinant spider silk produced by genetically engineered silkworms exhibits strength surpassing steel and toughness exceeding Kevlar while being fully biodegradable, driving applications in medicine, military, and high-performance textiles, showcasing sustainable potential.
- Defense Application Innovation: L3Harris Technologies has delivered over 1,000 carbon-fiber bomb casings, reducing dangerous shrapnel in urban operations and enhancing operational safety, highlighting the critical role of new materials in military applications.
- High-Performance Textiles Development: Kraig Biocraft Laboratories set a record of producing 1.3 metric tons of spider silk in April 2026, with a goal of reaching 10 metric tons per month to meet the demand for sustainable fabrics from high-end athletic and luxury brands, driving market growth.
- Aerospace Materials Advancement: Aspen Aerogels' next-generation aerogels are providing superior thermal management solutions for hypersonic vehicles and reusable spacecraft, marking the integration of aerospace technology with advanced materials and propelling future aerospace development.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Rivas's Background: Maria Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, where she oversaw the launch of multiple blockbuster medical products, and her expertise is expected to bolster Telix's capabilities in oncology and rare diseases.
- Jellison's Experience: William Jellison has over 30 years of corporate finance leadership experience, including serving as CFO of Stryker Corporation, where he managed international finance and M&A, and his financial acumen will provide critical strategic support for Telix.
- Strategic Implications: This board expansion aligns with Telix's evolution into a global commercial-stage biopharmaceutical company, reflecting the company's commitment to enhancing governance structures and increasing market competitiveness, which is expected to drive long-term growth in the biopharmaceutical industry.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
- William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
- Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
See More
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.
Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.
See More
Avient Corporation to Release Q1 2026 Earnings on May 7
- Earnings Release Schedule: Avient Corporation intends to release its Q1 2026 earnings before the market opens on May 7, 2026, which is expected to provide investors with insights into the latest financial performance and business developments.
- Webcast Meeting: The company will host a webcast at 8:00 a.m. Eastern Time on the same day, featuring a slide presentation that allows investors to receive real-time information and engage interactively.
- Participant Registration Requirement: Conference call participants must pre-register to obtain the dial-in number and personal PIN, ensuring smooth proceedings and effective information dissemination during the Q&A session.
- Information Accessibility: The webcast recording and slide presentation will be available immediately after the conference call and accessible for one year, enhancing investors' understanding and engagement with the company's updates.
See More
Advanced Materials Science Drives Industry Transformation
- Biomaterials Breakthrough: Recombinant spider silk produced by genetically engineered silkworms exhibits strength surpassing steel and elasticity exceeding Kevlar, already applied in medicine, military, and high-performance textiles, driving sustainability and functionality enhancements.
- Defense Application Innovation: L3Harris Technologies has delivered over 1,000 carbon-fiber bomb casings, reducing collateral damage in urban operations and enhancing operational efficiency, showcasing the immense potential of new materials in the military sector.
- High-Performance Textiles Progress: Kraig Biocraft Laboratories set a record of producing 1.3 metric tons of spider silk in April 2026, with a goal of reaching 10 metric tons monthly, meeting the luxury apparel market's demand for sustainable materials and transforming the textile industry.
- Aerospace Materials Innovation: Aspen Aerogels' next-generation aerogels are providing thermal protection for hypersonic vehicles and reusable spacecraft, marking the convergence of aerospace technology and advanced materials, driving technological advancements in the aerospace sector.
See More
Advanced Materials Technology Drives Industry Transformation
- Biomaterials Breakthrough: Recombinant spider silk produced by genetically engineered silkworms exhibits strength surpassing steel and toughness exceeding Kevlar while being fully biodegradable, driving applications in medicine, military, and high-performance textiles, showcasing sustainable potential.
- Defense Application Innovation: L3Harris Technologies has delivered over 1,000 carbon-fiber bomb casings, reducing dangerous shrapnel in urban operations and enhancing operational safety, highlighting the critical role of new materials in military applications.
- High-Performance Textiles Development: Kraig Biocraft Laboratories set a record of producing 1.3 metric tons of spider silk in April 2026, with a goal of reaching 10 metric tons per month to meet the demand for sustainable fabrics from high-end athletic and luxury brands, driving market growth.
- Aerospace Materials Advancement: Aspen Aerogels' next-generation aerogels are providing superior thermal management solutions for hypersonic vehicles and reusable spacecraft, marking the integration of aerospace technology with advanced materials and propelling future aerospace development.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Rivas's Background: Maria Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, where she oversaw the launch of multiple blockbuster medical products, and her expertise is expected to bolster Telix's capabilities in oncology and rare diseases.
- Jellison's Experience: William Jellison has over 30 years of corporate finance leadership experience, including serving as CFO of Stryker Corporation, where he managed international finance and M&A, and his financial acumen will provide critical strategic support for Telix.
- Strategic Implications: This board expansion aligns with Telix's evolution into a global commercial-stage biopharmaceutical company, reflecting the company's commitment to enhancing governance structures and increasing market competitiveness, which is expected to drive long-term growth in the biopharmaceutical industry.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
- William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
- Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
See More
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.
Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.
See More
Avient Corporation to Release Q1 2026 Earnings on May 7
- Earnings Release Schedule: Avient Corporation intends to release its Q1 2026 earnings before the market opens on May 7, 2026, which is expected to provide investors with insights into the latest financial performance and business developments.
- Webcast Meeting: The company will host a webcast at 8:00 a.m. Eastern Time on the same day, featuring a slide presentation that allows investors to receive real-time information and engage interactively.
- Participant Registration Requirement: Conference call participants must pre-register to obtain the dial-in number and personal PIN, ensuring smooth proceedings and effective information dissemination during the Q&A session.
- Information Accessibility: The webcast recording and slide presentation will be available immediately after the conference call and accessible for one year, enhancing investors' understanding and engagement with the company's updates.
See More
